Altimmune Expands Manufacturing Agreement for Covid-19 Vaccine Candidate
By Chris Wack
Altimmune Inc. said Friday it expanded its previously announced
AdCOVID manufacturing collaboration with Lonza.
Lonza will commission a dedicated manufacturing suite for
clinical and commercial production of AdCOVID, Altimmune's
single-dose intranasal vaccine candidate for Covid-19, at its
facility near Houston.
The biopharmaceutical company said that by expanding its Lonza
collaboration and commissioning its own dedicated manufacturing
suite, it is building extra capacity and redundancy into its
manufacturing to support potential late-stage clinical trials with
AdCOVID and potential future commercial supply.
AdCOVID is a Covid-19 vaccine candidate that is administered via
nasal spray. Altimmune believes that AdCOVID could provide immunity
of up to a year or more following a single dose with the potential
for a favorable tolerability profile. AdCOVID is expected to be
shipped without cold chain logistics, permitting common
refrigerated storage at community-based vaccination centers without
the need for specialized freezer storage.
Altimmune's shares rose 20% to $20.06 in premarket trading.
Write to Chris Wack at firstname.lastname@example.org
(END) Dow Jones Newswires
March 12, 2021 06:29 ET (11:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.